₹1.00
ABEVMY (Bevacizumab) is an anti-angiogenic medication. It works by interfering with the process of angiogenesis by blocking a protein called vascular endothelial growth factor (VEGF). This stops the formation of blood vessels that bring oxygen and nutrients to cancerous cells.
It is used in the treatment of metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCL), kidney cancer, brain tumor, ovarian and cervical cancer.
Available in Strenghts of 100mg & 400mg
| Trade Name | ABEVMY 100 |
|---|---|
| Generic Name | Bevacizumab |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Drug Type | Oncology |
| Indication | all cancers in descriptioj |
| Doasage Form | Injectible |
| Packaging | 1 x 15ml vial |
| Strength | 100mg, 400mg |
